To view this email as a web page, click here.
 
Top barriers to biosimilar approval and adoption in the US
From our sister brand, Managed Healthcare Executive: The biosimilar market is flourishing in Europe—why aren’t we seeing similar gains in the United States?
Read more
 
FDA approves first biosimilar to Rituxan
FDA approved the first biosimilar to rituximab (Rituxan) to treat non-Hodgkins lymphoma.
Read more
 
FDA clears novel cancer treatments
FDA recently approved 2 novel cancer treatments, including the second "precision medicine" cancer therapy based on a common biomarker across genes.
Read more
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.